Enterprise Value
211.2M
Cash
244.4M
Avg Qtr Burn
-39.62M
Short % of Float
4.84%
Insider Ownership
2.95%
Institutional Own.
87.83%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Rare diseases, Lung disease, Pulmonary arterial hypertension | Phase 3 Data readout | |
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Lung disease, Pulmonary hypertension associated with interstitial lung disease | Phase 3 Initiation | |
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis | Failed Discontinued | |
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer | Failed Discontinued | |
Failed Discontinued |